Migalastat (Galafold) (Amicus therapeutics)
The objective of this report was to perform a systematic review of the beneficial and harmful effects of migalastat 123 mg capsule (equivalent to 150 mg migalastat hydrochloride [HCl]) for long-term treatment of adults with a confirmed diagnosis of Fabry disease (FD) (deficiency of alpha-Gal A) and...
Corporate Author: | |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
CADTH
2018, February 2018
|
Series: | CADTH common drug review clinical review report
|
Subjects: | |
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | The objective of this report was to perform a systematic review of the beneficial and harmful effects of migalastat 123 mg capsule (equivalent to 150 mg migalastat hydrochloride [HCl]) for long-term treatment of adults with a confirmed diagnosis of Fabry disease (FD) (deficiency of alpha-Gal A) and who have an alpha-galactosidase A (alpha-Gal A) mutation determined to be amenable by an in vitro assay |
---|---|
Physical Description: | 1 PDF file (98 pages) illustrations |